vs
AdvanSix Inc.（ASIX）与医疗房产信托（SVC）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是医疗房产信托的1.2倍（$359.9M vs $296.5M），医疗房产信托净利率更高（-0.3% vs -0.8%，领先0.5%），AdvanSix Inc.同比增速更快（9.4% vs -17.0%），AdvanSix Inc.自由现金流更多（$36.1M vs $-95.2M），过去两年AdvanSix Inc.的营收复合增速更高（3.4% vs -6.1%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
医疗房产信托（MPT）是总部位于阿拉巴马州伯明翰的国际房地产投资信托（REIT），主要在美国和欧洲地区收购投资医疗设施与营利性医疗控股公司。该公司的房产收购多采用售后回租模式，原产权方出售房产给MPT后成为承租租户，其租户普遍签订长期三净租约。
ASIX vs SVC — 直观对比
营收规模更大
ASIX
是对方的1.2倍
$296.5M
营收增速更快
ASIX
高出26.4%
-17.0%
净利率更高
SVC
高出0.5%
-0.8%
自由现金流更多
ASIX
多$131.3M
$-95.2M
两年增速更快
ASIX
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $296.5M |
| 净利润 | $-2.8M | $-782.0K |
| 毛利率 | 7.6% | — |
| 营业利润率 | -0.7% | -3.9% |
| 净利率 | -0.8% | -0.3% |
| 营收同比 | 9.4% | -17.0% |
| 净利润同比 | -892.9% | 99.0% |
| 每股收益（稀释后） | $-0.11 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXSVC
| Q4 25 | $359.9M | $296.5M | ||
| Q3 25 | $374.5M | $377.6M | ||
| Q2 25 | $410.0M | $404.4M | ||
| Q1 25 | $377.8M | $335.0M | ||
| Q4 24 | $329.1M | $357.0M | ||
| Q3 24 | $398.2M | $390.9M | ||
| Q2 24 | $453.5M | $412.5M | ||
| Q1 24 | $336.8M | $336.2M |
净利润ASIXSVC
| Q4 25 | $-2.8M | $-782.0K | ||
| Q3 25 | $-2.6M | $-46.9M | ||
| Q2 25 | $31.4M | $-38.2M | ||
| Q1 25 | $23.3M | $-116.4M | ||
| Q4 24 | $352.0K | $-76.4M | ||
| Q3 24 | $22.3M | $-46.9M | ||
| Q2 24 | $38.9M | $-73.8M | ||
| Q1 24 | $-17.4M | $-78.4M |
毛利率ASIXSVC
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
营业利润率ASIXSVC
| Q4 25 | -0.7% | -3.9% | ||
| Q3 25 | -0.9% | -12.8% | ||
| Q2 25 | 7.7% | -9.2% | ||
| Q1 25 | 7.7% | -33.3% | ||
| Q4 24 | -3.9% | -19.4% | ||
| Q3 24 | 7.5% | -12.8% | ||
| Q2 24 | 11.5% | -17.1% | ||
| Q1 24 | -7.0% | -21.4% |
净利率ASIXSVC
| Q4 25 | -0.8% | -0.3% | ||
| Q3 25 | -0.7% | -12.4% | ||
| Q2 25 | 7.7% | -9.4% | ||
| Q1 25 | 6.2% | -34.8% | ||
| Q4 24 | 0.1% | -21.4% | ||
| Q3 24 | 5.6% | -12.0% | ||
| Q2 24 | 8.6% | -17.9% | ||
| Q1 24 | -5.2% | -23.3% |
每股收益（稀释后）ASIXSVC
| Q4 25 | $-0.11 | $-0.01 | ||
| Q3 25 | $-0.10 | $-0.28 | ||
| Q2 25 | $1.15 | $-0.23 | ||
| Q1 25 | $0.86 | $-0.70 | ||
| Q4 24 | $0.02 | $-0.46 | ||
| Q3 24 | $0.82 | $-0.28 | ||
| Q2 24 | $1.43 | $-0.45 | ||
| Q1 24 | $-0.65 | $-0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $346.8M |
| 总债务越低越好 | — | $5.5B |
| 股东权益账面价值 | $815.2M | $646.1M |
| 总资产 | $1.7B | $6.5B |
| 负债/权益比越低杠杆越低 | — | 8.52× |
8季度趋势，按日历期对齐
现金及短期投资ASIXSVC
| Q4 25 | $19.8M | $346.8M | ||
| Q3 25 | $23.7M | $417.4M | ||
| Q2 25 | $18.4M | $63.2M | ||
| Q1 25 | $8.3M | $80.1M | ||
| Q4 24 | $19.6M | $143.5M | ||
| Q3 24 | $17.3M | $48.6M | ||
| Q2 24 | $12.1M | $14.6M | ||
| Q1 24 | $20.6M | $71.3M |
总债务ASIXSVC
| Q4 25 | — | $5.5B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $5.8B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASIXSVC
| Q4 25 | $815.2M | $646.1M | ||
| Q3 25 | $818.2M | $647.9M | ||
| Q2 25 | $823.7M | $695.9M | ||
| Q1 25 | $794.4M | $734.6M | ||
| Q4 24 | $774.6M | $851.9M | ||
| Q3 24 | $766.4M | $929.0M | ||
| Q2 24 | $746.6M | $1.0B | ||
| Q1 24 | $713.2M | $1.1B |
总资产ASIXSVC
| Q4 25 | $1.7B | $6.5B | ||
| Q3 25 | $1.7B | $7.0B | ||
| Q2 25 | $1.6B | $6.9B | ||
| Q1 25 | $1.6B | $7.0B | ||
| Q4 24 | $1.6B | $7.1B | ||
| Q3 24 | $1.5B | $7.1B | ||
| Q2 24 | $1.5B | $7.1B | ||
| Q1 24 | $1.5B | $7.2B |
负债/权益比ASIXSVC
| Q4 25 | — | 8.52× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.85× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $-18.5M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $-95.2M |
| 自由现金流率自由现金流/营收 | 10.0% | -32.1% |
| 资本支出强度资本支出/营收 | 7.7% | 25.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | $-107.0M |
8季度趋势，按日历期对齐
经营现金流ASIXSVC
| Q4 25 | $63.7M | $-18.5M | ||
| Q3 25 | $26.6M | $98.1M | ||
| Q2 25 | $21.1M | $-7.0K | ||
| Q1 25 | $11.4M | $38.2M | ||
| Q4 24 | $64.2M | $-9.7M | ||
| Q3 24 | $57.3M | $106.2M | ||
| Q2 24 | $50.2M | $43.8M | ||
| Q1 24 | $-36.2M | $-926.0K |
自由现金流ASIXSVC
| Q4 25 | $36.1M | $-95.2M | ||
| Q3 25 | $66.0K | $57.9M | ||
| Q2 25 | $-7.2M | $-46.6M | ||
| Q1 25 | $-22.6M | $-23.2M | ||
| Q4 24 | $29.8M | $-88.9M | ||
| Q3 24 | $26.8M | $24.1M | ||
| Q2 24 | $16.7M | $-22.3M | ||
| Q1 24 | $-71.6M | $-77.2M |
自由现金流率ASIXSVC
| Q4 25 | 10.0% | -32.1% | ||
| Q3 25 | 0.0% | 15.3% | ||
| Q2 25 | -1.7% | -11.5% | ||
| Q1 25 | -6.0% | -6.9% | ||
| Q4 24 | 9.1% | -24.9% | ||
| Q3 24 | 6.7% | 6.2% | ||
| Q2 24 | 3.7% | -5.4% | ||
| Q1 24 | -21.3% | -23.0% |
资本支出强度ASIXSVC
| Q4 25 | 7.7% | 25.9% | ||
| Q3 25 | 7.1% | 10.6% | ||
| Q2 25 | 6.9% | 11.5% | ||
| Q1 25 | 9.0% | 18.3% | ||
| Q4 24 | 10.4% | 22.2% | ||
| Q3 24 | 7.7% | 21.0% | ||
| Q2 24 | 7.4% | 16.0% | ||
| Q1 24 | 10.5% | 22.7% |
现金转化率ASIXSVC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
SVC
暂无分部数据
